Miracor Medical Systems Launches PICSO Impulse System in Asia

September 21, 2015— Miracor Medical Systems GmbH announced the launch the PICSOAIM (pressure-controlled intermittent coronary sinus occlusion—acute myocardial infarction) Impulse system in markets in Asia. The PICSO Impulse system has also received CE Mark approval for sale in Europe.

The PICSOAIM Impulse system is designed to treat acute ST-segment elevation myocardial infarction (STEMI) and non-STEMI patients by improving myocardial perfusion in complement with percutaneous coronary intervention (PCI). PICSOAIM is applied during PCI and is designed to intermittently block the coronary sinus, thereby increasing perfusion of the myocardium and reducing injury resulting from myocardial infarction.

The first cases using the PICSOAIM Impulse system were performed by Arif Al Nooryani, MD, who is Chief Executive Officer and Head of the Cardiac Center at Al Qassimi Hospital in Sharjah, United Arab Emirates (UAE). The company noted that the procedures in the UAE were performed with the support of Access Medical LLC, a UAE-based medical devices distributor and sister company of Medical Technology Est., which is cooperating with Miracor to launch the PICSOAIM Impulse system in the Kingdom of Saudi Arabia, Kuwait, and Oman.

In the company’s press release, Dr. Al Nooryani commented, “We applied PICSO therapy during complex PCI procedures, treating non-STEMI patients. Directly following diagnostic angiography, we initiated PICSO therapy for the duration of the complex stenting procedures to improve myocardial perfusion.”

He added, “I was impressed to see the immediate effect of PICSO, as my patients did not experience chest pain, nor did we see electrocardiography changes or signs of no-reflow phenomena, which can normally be expected during such procedures. This demonstrates the positive effects of PICSO on myocardial perfusion. I now look forward to making this therapy available for our AMI patients at Al Qassimi Hospital.”